心脏沙丘病的设备治疗:当前的审查,挑战和未来的前景
Mohamed ElRefai1, Christina Menexi2, Paul R Roberts3,4
1Cardiology Department, University Hospital of Cambridge, Cambridge, UK.
The Journal of innovations in cardiac rhythm management
|November 20, 2024
概括
心脏类沙尔科毒症是一种心脏病,具有诊断挑战和风险 突然心脏病死亡 (SCD). 新型疗法,如无节奏与皮下植入式心脏转换器-除器 (S-ICD) 显示承诺为服务不足的患者.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 医疗器械 医疗器械
背景情况:
- 沙尔科病是影响多个器官的炎症性疾病,心脏参与带来了重大诊断和治疗挑战.
- 心脏沙丘症可能导致严重的心律失常和心脏突然死亡 (SCD),需要有效的预防策略.
- 目前对植入式心脏转换器-除器 (ICD) 的指导方针可能不涵盖所有有风险的心脏沙丘病患者.
研究的目的:
- 探讨诊断和管理心脏沙病的挑战,特别是关于SCD风险.
- 评估新型器械治疗的潜力,包括皮下ICD和无节奏控制,用于控制心脏沙丘症.
- 强调需要个性化的方法来治疗心脏类病患有SCD风险的患者.
主要方法:
- 审查当前的诊断标准和治疗心脏沙丘病的指导方针.
- 在免疫抑制患者中分析与传统的静脉输血ICD相关的局限性和并发症.
- 探索S-ICD和无定律的新兴作用,参考正在进行的临床试验.
主要成果:
- 诊断心脏沙尔科发症是复杂的,需要先进的成像和组织学.
- 传统的ICD带有风险,并非所有患者都符合植入标准,造成护理的差距.
- S-ICD为输血器件提供了替代方案,减轻了血管和感染风险,但存在诸如不适当的冲击和缺乏节奏等局限性.
结论:
- 与S-ICD相结合的无节奏测试为心脏沙丘病患者提供了一个有希望的,个性化的治疗策略.
- 这种新的方法可能会解决传统器械疗法服务不足的心脏沙丘病患者未得到满足的需求.
- 进一步的临床研究至关重要,以确定S-ICD和无节奏组合的安全性和有效性,以预防这一群体的SCD.
更多相关视频
10:39Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
Published on: August 30, 2024
557
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
7.7K
相关概念视频
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:26Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:22Myocarditis IV: Nursing Management
2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2
01:20Rheumatic Heart Disease IV: Nursing Management
4
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
4
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386